Details for Patent: 10,391,094

Which drugs does patent 10,391,094 protect, and when does it expire?

Patent 10,391,094 protects INREBIC and is included in one NDA.

This patent has forty-seven patent family members in thirty-four countries.

Summary for Patent: 10,391,094

Title:	Compositions and methods for treating myelofibrosis
Abstract:	Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyr- imidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
Inventor(s):	Jayan; Arvind (La Jolla, CA), Cacace; Janice (Miami, FL)
Assignee:	Impact Biomedicines, Inc. (Summit, NJ)
Application Number:	13/888,096
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,391,094
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,391,094

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes			Y			TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS

International Family Members for US Patent 10,391,094

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010363329
Australia	2011323108
Brazil	112013011184
Canada	2816710
Canada	2816957
Chile	2013001252